港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

武漢艾米森生命科技股份有限公司（臨時代碼）

成交量：- -

成交額：- -

市值：- -

市盈率：- -

高：- -

開：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：- -

香港流通股本：- -

量比：- -

換手率：- -

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

市銷率: - -

資料載入中...

總覽公司新聞資訊公告

新股消息 | 艾米森擬港股上市中國證監會要求補充説明股權變動等事項

艾米森衝港股年營收不足千萬元關聯交易撐起半邊天

艾米森衝刺港股半數收入涉關聯交易

癌症早篩公司艾米森IPO：營收額不足千萬靠縮減費用減虧關聯方或股東貢獻超6成營收

早期癌症檢測公司艾米森闖港股：年入不足千萬，關聯交易撐起半邊天

创业最前线

艾米森生命科技-B，來自湖北武漢，遞交IPO招股書，擬赴香港上市，建銀國際、交銀國際聯席保薦

新股消息 | 艾米森遞表港交所，為領先的早期癌症檢測公司

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/91270/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"91270","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91270\",,,,,undefined,":{"symbol":"91270","market":"HK","secType":"STK","nameCN":"武漢艾米森生命科技股份有限公司（臨時代碼）","latestPrice":0,"timestamp":1774512000000,"preClose":0,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":0,"latestTime":"03-26 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1774575000000},"marketStatusCode":0,"adr":0,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1774488600000,1774497600000],[1774501200000,1774512000000]],"volumeRatio":0,"lotSize":0,"spreadScale":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91270\",,,,,undefined,":{"symbol":"91270","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/91270\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"91270\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"91270\",market:\"HK\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"91270\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2583950807","title":"新股消息 | 艾米森擬港股上市 中國證監會要求補充説明股權變動等事項","url":"https://stock-news.laohu8.com/highlight/detail?id=2583950807","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583950807?lang=zh_tw&edition=fundamental","pubTime":"2025-11-14 19:57","pubTimestamp":1763121472,"startTime":"0","endTime":"0","summary":"中国证监会国际司公示10家企业补充材料要求，其中，公示提到要求艾米森补充说明股权变动、股东情况、业务经营等事项。据港交所9月28日披露，武汉艾米森生命科技股份有限公司向港交所主板提交上市申请书，联席保荐人为建银国际、交银国际。招股书显示，艾米森是一家领先的早期癌症检测公司，战略聚焦于高发病率、高死亡率的癌症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91270"],"gpt_icon":0},{"id":"2579634451","title":"艾米森衝港股年營收不足千萬元 關聯交易撐起半邊天","url":"https://stock-news.laohu8.com/highlight/detail?id=2579634451","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579634451?lang=zh_tw&edition=fundamental","pubTime":"2025-10-30 11:08","pubTimestamp":1761793690,"startTime":"0","endTime":"0","summary":"中国经济网北京10月30日讯 近日，武汉艾米森生命科技股份有限公司 向港交所递交上市申请，联席保荐人为建银国际与交银国际。　　新浪证券近日刊载《癌症早筛公司艾米森IPO：营收额不足千万靠缩减费用减亏 关联方或股东贡献超6成营收》。文章指出，2023年、2024年及2025年上半年，艾米森的收入分别为623.3万元、723.8万元和651.3万元。尽管2025年上半年同比增长103%，但整体营收规模仍不足千万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20251030/31750212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["91270"],"gpt_icon":0},{"id":"2579491990","title":"艾米森衝刺港股 半數收入涉關聯交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2579491990","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579491990?lang=zh_tw&edition=fundamental","pubTime":"2025-10-29 04:35","pubTimestamp":1761683700,"startTime":"0","endTime":"0","summary":"　　近日，武汉艾米森生命科技股份有限公司向港交所递交上市申请，联席保荐人为建银国际与交银国际。　　作为一家成立于2015年的公司，艾米森聚焦近年来兴起的癌症早筛技术，自称旗下核心产品艾光乐仅需用1毫升尿液样本即可实现尿路上皮癌的非侵入性检测。但前沿技术的背后，公司至今仍未盈利，还存在研发投入存疑和大额关联交易的情况。　　回顾艾米森近年来的业绩表现，大额的关联交易无疑是不容忽视的一环。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-10-29/doc-infvnxkx8370951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91270"],"gpt_icon":0},{"id":"2577552077","title":"癌症早篩公司艾米森IPO：營收額不足千萬靠縮減費用減虧 關聯方或股東貢獻超6成營收","url":"https://stock-news.laohu8.com/highlight/detail?id=2577552077","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577552077?lang=zh_tw&edition=fundamental","pubTime":"2025-10-24 10:38","pubTimestamp":1761273480,"startTime":"0","endTime":"0","summary":"　　近日，武汉艾米森生命科技股份有限公司正式向港交所递交招股书，联席保荐人为建银国际与交银国际。艾米森成立于2015年、专注于癌症早期筛查的体外诊断公司，愿景是成为全球肿瘤早筛的领先者。艾米森的上市尝试，恰逢行业标杆企业诺辉健康因财务造假停牌18个月、面临退市危机。被誉为中国癌症早筛第一股的企业坠落神坛，让整个行业笼罩在阴影之中。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-10-24/doc-infuyerp1519536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91270"],"gpt_icon":0},{"id":"2577282958","title":"早期癌症檢測公司艾米森闖港股：年入不足千萬，關聯交易撐起半邊天","url":"https://stock-news.laohu8.com/highlight/detail?id=2577282958","media":"创业最前线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577282958?lang=zh_tw&edition=fundamental","pubTime":"2025-10-21 00:08","pubTimestamp":1760976537,"startTime":"0","endTime":"0","summary":"招股书显示，艾米森2024年全年实现收入723.8万元，同比增长16.1%，但规模仍不足一千万元。若按每次检测800元左右估算，其年检测量或不足万例。根据招股书披露，截至最后实际可行日期，凯普生物的控股公司广东凯普生物持有其61%股权，因此广东凯普及其附属公司被界定为艾米森的关连人士。目前，凯普生物共持有艾米森约11.69%股权，位列主要股东之一。与此前的征求意见稿相比，文件明确了癌症筛查产品的受试者为无症状人群，切断","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021001131a46a8b46&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021001131a46a8b46&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1219","06606","BK1574","91270"],"gpt_icon":0},{"id":"2572959489","title":"艾米森生命科技-B，來自湖北武漢，遞交IPO招股書，擬赴香港上市，建銀國際、交銀國際聯席保薦","url":"https://stock-news.laohu8.com/highlight/detail?id=2572959489","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572959489?lang=zh_tw&edition=fundamental","pubTime":"2025-10-02 12:58","pubTimestamp":1759381080,"startTime":"0","endTime":"0","summary":"　　2025年9月28日，来自湖北武汉东湖新技术开发区的武汉艾米森生命科技股份有限公司Wuhan Ammunition Life-tech Co．， Ltd．在港交所递交招股书，拟在香港主板挂牌上市。　　艾米森，成立于2015年，作为一家领先的早期癌症检测公司，战略聚焦于高发病率、高死亡率的癌症。AMStation预计将于2026年初完成EMC检测及安全合规性测试，并向湖北省武汉市市场监督管理局提交第一类医疗器械注册申请。　　建银国际、交银国际为其联席保荐人；","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2025-10-02/doc-infsnqmq6301103.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03329","BK1147","91270"],"gpt_icon":0},{"id":"2571820983","title":"新股消息 | 艾米森遞表港交所，為領先的早期癌症檢測公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2571820983","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571820983?lang=zh_tw&edition=fundamental","pubTime":"2025-09-29 06:43","pubTimestamp":1759099416,"startTime":"0","endTime":"0","summary":"招股书显示，艾米森是一家领先的早期癌症检测公司，战略聚焦于高发病率、高死亡率的癌症。公司深耕中国高速增长的肿瘤分子检测市场。为把握这一市场机遇并响应中国未被满足的早期癌症检测需求，公司已开发一个具有多重竞争优势的综合早期癌症检测平台。财务方面，于2023年度、2024年度及2025年截至6月30日止六个月，艾米森实现收入分别为623.3万元、723.8万元、651.3万元人民币；年度亏损分别为6792.2万元、3863万元、1390.6万元人民币。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350355.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91270"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}]}}